Simvastatin prevents the development of pulmonary hypertension in the rats through reduction of inflammation

National Medical Journal of China

Volumn 89, Issue 12, 2009, Pages 855-859

  Zhang, Wei Hua ^a   Lu, Wei Xuan ^a   Zhang, Yun Jian ^b   Ji, Ying Qun ^b   Liu, Chun Ping ^b   Li, Guo ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NONE

Author keywords

Hypertension, pulmonary; Inflammation; Monocrotaline; Rats, Sprague Dawley; Simvastatin

Indexed keywords

INTERLEUKIN 6; MONOCROTALINE; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART CATHETER; INFLAMMATION; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PROTECTION; PULMONARY HYPERTENSION; RAT; SCORING SYSTEM; TREATMENT DURATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; HYPERTENSION, PULMONARY; INTERLEUKIN-6; MALE; MONOCROTALINE; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954942100     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.12.016     Document Type: Article

References (28)

1. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol, 1994,144:275-285.
2. Dorfmüller P, Perros F, Balabaniam K, et al. Inflammation in pulmonary arterial hypertension. Eur Respir J, 2003,22:358-363.
3. Kinlay S. Potential vascular benefits of statins. Am J Med, 2005,118(Suppl 12A):62-67.
4. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-imflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol, 2001,21:115-121.
5. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med, 2000,6:1399-1402.
6. Frenette PS. Locking a leukocyte integrin with statins. N Engl J Med, 2001,345:1419-1421.
7. Marz W, Koenig W. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk, 2003,10:169-179.
8. Campian ME, Hardziyenka M, Michel MC, et al. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol, 2006,373:391-400.
9. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002,165:1419-1425. (Pubitemid 34522947)
10. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentration in severe primary pulmonary hypertension. Am J Respir Crit Care Med, 1995,151:1628-1631.
11. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J, 1998,11:554-559.
12. Fartoukh M, Emilie D, Le Gall C, et al. Chemokine macrophage inflammatory protein-1 alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest, 1998,114:50-51.
13. Dorfmüller P, Zarka V, Durand-Gasselin I, et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med, 2002,165:534-539. (Pubitemid 34165478)
14. Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax, 1999,54:273-277.
15. Bellotto F, Chiavacei P, Laveder F, et al. Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax, 1999,54:372-374.
16. Karmochkine M, Wechsler B, Godeau P, et al. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis, 1996,55:561-562.
17. Morelli S, Giordano M, De Marzio P, et al. Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus. Lupus, 1993,2:367-369.
18. LALICH JJ, MERKOW L. Pulmonary arteries produced in rats by feeding Crotolaria spectabilis. Lab Invest, 1961,10:744-750.
19. Faul JL, Nishimura T, Berry GJ, et al. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med, 2000,162:2252-2258.
20. Nishimura T, Faul JL, Berry GJ, et al. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med, 2001,163:498-502.
21. Sheikine Y, Hansson GK. Chemokine and atherosclerosis. Ann Med, 2004,36:98-118.
22. Bellisarii FL, Gallina S, De Caterina R. Tumor nercosis factor-alpha and cardiovascular diseases. Ital Heart J, 2001,2:408-417.
23. Nishimura T, Vsazar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003,108:1640-1645.
24. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med, 2002,166:1403-1408.
25. Murata T, Sato K, Hori M, et al. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem, 2002,277:44085-44092.
26. Murata T, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol, 2005,25:2335-2342.
27. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol, 2003,285:H938-945.